The Journal of Pediatrics
Volume 148, Issue 4 , Pages 489-494 , April 2006

Single dose of anti-D immune globulin at 75μg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children

Received 21 April 2005 ,Revised 25 October 2005 ,Accepted 3 November 2005.

References 

  1. Nugent DJ. Immune thrombocytopenic purpura (why treat?). J Pediatr. 1999;134:3–4
  2. Bolton-Maggs PHB, Dickeroff R, Vora AJ. The nontreatment of childhood ITP (or “the art of medicine consists of amusing the patient until nature cures the disease”). Semin Thromb Hemost. 2001;27:269–275
  3. de Alarcon PA. Immune or idiopathic thrombocytopenic purpura (ITP) in childhood (what are the risks and who should be treated?). J Pediatr. 2003;143:287–289
  4. Buchanan GR. Childhood acute thrombocytopenic purpura (how many tests and how much treatment required?). J Pediatr. 1985;106:928–932
  5. Lilleyman J. Medical nemesis and childhood ITP. Br J Haematol. 2003;123:586–589
  6. Buchanan GR, de Alarcon PA, Feig SA, Gilchrist GS, Lukens JN, Moertel CL, et al. Acute idiopathic thrombocytopenic purpura—management in childhood. [letter] Blood. 1997;89:1464–1465
  7. Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr. 2000;137:629–632
  8. Tarantino MD. On the conservative management of acute immune thrombocytopenia in children. J Pediatr. 2001;138:787–788
  9. Bolton-Maggs P, Tarantino MD, Buchannan G, Bussel J, George JN. The child with immune thrombocytopenic purpura (is pharmacotherapy or watchful waiting the best initial management? A panel discussion from the 2002 meeting of the American Society of Pediatric Hematology/Oncology). J Pediatric Hematol/Oncol. 2004;26:146–151
  10. Vesely SK, Buchanan GR, Adix L, George JN, Cohen AR, Blanchette VS, et al. Self-reported initial management of childhood idiopathic thrombocytopenic purpura (results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001). J Pediatr Hematol/Oncol. 2003;25:130–133
  11. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707
  12. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura (experience in 272 patients). Blood. 1997;89:2689–2700
  13. Tarantino MD, Madden RM, Fennewald DL, Patel CC, Bertolone SJ. Efficacy of anti-D immunoglobulin vs. intravenous pooled immunoglobulin G in the initial treatment of acute immune thrombocytopenic purpura in children. J Pediatr. 1999;134:21–26
  14. Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol. 2001;112:1076–1078
  15. Andrew M, Blanchette VS, Adams M, Ali K, Barnard D, Chan KW, et al. A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D. J Pediatr. 1992;120:522–527
  16. Bussel JB, Goldman A, Imbach P, Schulman I, Hilgartner MW. Treatment of acute idiopathic thrombocytopenic purpura of childhood with intravenous infusions of gammaglobulin. J Pediatr. 1985;106:886–890
  17. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous Immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464–468
  18. Warrier I, Bussel JB, Valdez L, Barbosa J, Beardsley DS. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. J Pediatr Hematol/Oncol. 1997;19:197–201
  19. Benesch M, Kerbl R, Lackner H, Berghold A, Schwinger W, Triebl-Roth K, et al. Low-dose versus high-dose immunoglobulin for primary treatment of acute immune thrombocytopenic purpura in children (results of a prospective, randomized single-center trial). J Pediatr Hematol/Oncol. 2003;25:797–800
  20. Bieri D, Reeve RA, Champion GD, Addicoat L, Ziegler JB. The faces pain scale for the self-assessment of the severity of pain experienced by children (development, initial validation, and preliminary investigation for ratio scale properties). Pain. 1990;41:139–150
  21. Beyer JE, Denyes MJ, Villarruel AM. The creation, validation, and continuing development of the Oucher (a measure of pain intensity in children). J Pediatr Nurs. 1992;7:335–346
  22. Blanchette VS, Luke B, Andrew M, Sommerville-Nielsen S, Barnard D, de Veber B, et al. A prospective, randomized trial of high-dose intravenous gammaglobulin G therapy, oral prednisone therapy and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr. 1993;123:989–995
  23. Butros LJ, Bussel JB. Intracranial hemorrhage in immune thrombocytopenic purpura (a retrospective analysis). J Pediatr Hematol/Oncol. 2003;25:660–664
  24. Kirovski A, Gregoire-Bottex M, Harris ME, Bussel JB. Intracranial hemorrhage in children with acute and chronic immune thrombocytopenic purpura. Blood. 2002;100:480a–481a
  25. Kuhne T, Buchanan GR, Zimmerman S, Michaels LA, Kohan R, Berchtold W, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group. J Pediatr. 2003;143:605–608
  26. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura (immediate response to therapy and long-term outcome). J Pediatr. 1998;133:334–339
  27. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141:683–688
  28. Monteleone PM, Vander Heyden MA, Steele DA, Kelleher JF. Anti-D immunoglobulin in children with newly diagnosed immune thrombocytopenic purpura (a pilot study). Haematologica. 2000;85:887–888
  29. Kees-Folts D, Abt AB, Domen RE, Freiberg AS. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Pediatr Nephrol. 2002;17:91–96
  30. Levendoglu-Tugal O, Jayabose S. Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia. J Pediatr Hematol/Oncol. 2001;23:460–463
  31. Olofinboba KA, Greenberg BR. Successful treatment of infectious mononucleosis-associated immune thrombocytopenia with WinRho anti-D immunoglobulin complicated by severe hemolysis. Am J Hematol. 2000;65:178
  32. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95:2523–2529

 Supported by Nabi. Employees of Nabi were not involved, in any way, in the study execution, data collection or analysis, decision to submit the data for publication, or preparation of the manuscript. No grant or honorarium was given to any author to produce the manuscript.

PII: S0022-3476(05)01089-9

doi: 10.1016/j.jpeds.2005.11.019

The Journal of Pediatrics
Volume 148, Issue 4 , Pages 489-494 , April 2006

Article Tools

* Image Usage & Resolution